The biotech industry is facing funding cuts, market volatility, and rising competition from China. Explore how companies are adapting to these pressures and what’s driving faster IRB reviews in this Trendline.
For nearly a decade, biotech companies and their venture backers enjoyed a historic boom. Although momentum has come to a halt, many of the largest venture investors remain flush with cash, while progress in gene editing, messenger RNA and cell therapies promise new kinds of medicines in the future.
included in this trendline
- 5 questions facing biopharma in 2026
- On biotech’s biggest stage, renewed excitement gets a stress test
- ‘The bar has risen’: China’s biotech gains push US companies to adapt
Offered Free by: BioPharma Dive and Brany
See All Resources from: BioPharma Dive and Brany
